BiomX (PHGE) Net Cash Flow (2018 - 2026)
BiomX (PHGE) posted Net Cash Flow of -$3.8 million for Q1 2026, down 20.84% sequentially from -$3.1 million in Q4 2025, and down 216.45% YoY from $3.3 million in Q1 2025.
BiomX (PHGE) Net Cash Flow (2018 - 2026) Analysis & Trends
BiomX has reported Net Cash Flow for 9 years, with the latest figure at -$3.8 million in Q1 2026.
- Quarterly Net Cash Flow fell 216.45% year-over-year to -$3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$20.1 million (up 12.16% YoY) and the FY2025 annual result came in at -$13.1 million, down 720.52% from the prior year.
- Net Cash Flow fell to -$3.8 million in Q1 2026 per PHGE's latest filing, from -$3.1 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $3.3 million in Q1 2025 and troughed at -$17.3 million in Q1 2022.
- A 5-year average of -$5.6 million and a median of -$6.4 million in 2024 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2023 and 2024: Net Cash Flow surged 105.65% in 2023, then sank 2932.34% in 2024.
- Over 5 years, Net Cash Flow stood at -$5.7 million in 2022, then slumped by 32.84% to -$7.6 million in 2023, then advanced by 11.67% to -$6.7 million in 2024, then surged by 53.14% to -$3.1 million in 2025, then retreated by 20.84% to -$3.8 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$3.8 million, -$3.1 million, and -$7.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | BiomX | 361,408.40 | -806,591.60 | - | -3.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.79 Mn |
| Mar 31, 2026 | -3.79 Mn |
| Dec 31, 2025 | -3.13 Mn |
| Dec 31, 2025 | -3.13 Mn |
| Sep 30, 2025 | -7.13 Mn |
| Sep 30, 2025 | -7.13 Mn |
| Jun 30, 2025 | -6.08 Mn |
| Jun 30, 2025 | -6.08 Mn |
| Mar 31, 2025 | 3.25 Mn |
| Mar 31, 2025 | 3.25 Mn |
| Dec 31, 2024 | -6.69 Mn |
| Dec 31, 2024 | -6.69 Mn |
| Sep 30, 2024 | -8.10 Mn |
| Sep 30, 2024 | -8.10 Mn |
| Jun 30, 2024 | -11.39 Mn |
| Jun 30, 2024 | -11.39 Mn |
| Dec 31, 2023 | -7.57 Mn |
| Dec 31, 2023 | -7.57 Mn |
| Sep 30, 2023 | -7.26 Mn |
| Sep 30, 2023 | -7.26 Mn |